Horan Capital Advisors LLC. bought a new position in Biogen Inc. (NASDAQ:BIIB) in the third quarter, according to its most recent disclosure with the SEC. The firm bought 410 shares of the biotechnology company’s stock, valued at approximately $128,000.

Several other institutional investors and hedge funds also recently modified their holdings of BIIB. Prentiss Smith & Co. Inc. increased its stake in shares of Biogen by 14.9% in the 2nd quarter. Prentiss Smith & Co. Inc. now owns 385 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 50 shares during the last quarter. Atlantic Trust LLC acquired a new stake in shares of Biogen during the 2nd quarter worth about $114,000. Independent Portfolio Consultants Inc. increased its position in shares of Biogen by 93.2% during the 2nd quarter. Independent Portfolio Consultants Inc. now owns 454 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 219 shares during the last quarter. Massey Quick Simon & CO. LLC increased its position in shares of Biogen by 84.8% during the 3rd quarter. Massey Quick Simon & CO. LLC now owns 425 shares of the biotechnology company’s stock worth $133,000 after purchasing an additional 195 shares during the last quarter. Finally, Carroll Financial Associates Inc. increased its position in shares of Biogen by 1.2% during the 2nd quarter. Carroll Financial Associates Inc. now owns 496 shares of the biotechnology company’s stock worth $134,000 after purchasing an additional 6 shares during the last quarter. 88.28% of the stock is owned by institutional investors and hedge funds.

Shares of Biogen Inc. (NASDAQ BIIB) traded up $0.74 during trading on Thursday, reaching $309.80. The company had a trading volume of 693,571 shares, compared to its average volume of 1,501,396. Biogen Inc. has a 12 month low of $244.28 and a 12 month high of $348.84. The stock has a market cap of $65,359.05, a PE ratio of 14.31, a price-to-earnings-growth ratio of 1.93 and a beta of 0.72. The company has a quick ratio of 1.90, a current ratio of 2.19 and a debt-to-equity ratio of 0.46.

Biogen (NASDAQ:BIIB) last announced its earnings results on Tuesday, October 24th. The biotechnology company reported $6.31 EPS for the quarter, beating analysts’ consensus estimates of $5.70 by $0.61. Biogen had a return on equity of 38.51% and a net margin of 29.44%. The company had revenue of $3.08 billion during the quarter, compared to analysts’ expectations of $3.05 billion. During the same period last year, the business posted $5.19 EPS. Biogen’s revenue for the quarter was up 4.1% on a year-over-year basis. equities research analysts anticipate that Biogen Inc. will post 22.03 EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/11/23/horan-capital-advisors-llc-takes-position-in-biogen-inc-biib.html.

A number of analysts recently issued reports on the company. Oppenheimer Holdings, Inc. reissued a “buy” rating and set a $350.00 price objective on shares of Biogen in a research report on Wednesday. Mizuho set a $400.00 price objective on Biogen and gave the stock a “buy” rating in a research report on Monday, November 13th. Vetr raised Biogen from a “buy” rating to a “strong-buy” rating and set a $319.53 price objective for the company in a research report on Thursday, August 10th. Cowen and Company reissued a “buy” rating on shares of Biogen in a research report on Thursday, July 27th. Finally, Goldman Sachs Group, Inc. (The) raised Biogen from a “buy” rating to a “conviction-buy” rating and set a $338.00 price objective for the company in a research report on Wednesday, August 16th. Twelve analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $341.89.

Biogen Company Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Stock Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related stocks with our FREE daily email newsletter.